C. M. Papke

Quantitative proteomics and phosphoproteomics of PP2A-PPP2R5D variants reveal deregulation of RPS6 phosphorylation via converging signaling cascades

Chun Xing Li, A. Kettenbach, A. Musiyenko, 2023, The Journal of biological chemistry.

A disorder-related variant (E420K) of a PP2A-regulatory subunit (PPP2R5D) causes constitutively active AKT-mTOR signaling and uncoordinated cell growth

W. Chung, Yufeng Shen, Liyong Deng, 2021, The Journal of biological chemistry.

The Antitumor Drug LB-100 Is a Catalytic Inhibitor of Protein Phosphatase 2A (PPP2CA) and 5 (PPP5C) Coordinating with the Active-Site Catalytic Metals in PPP5C

R. Honkanen, M. Swingle, A. Prakash, 2019, Molecular Cancer Therapeutics.

The Antitumor Drug LB-100 Is a Catalytic Inhibitor of Protein Phosphatase 2A (PPP2CA) and 5 (PPP5C) Coordinating with the Active-Site Catalytic Metals in PPP5C

R. Honkanen, M. Swingle, Kevin A. Abney, 2019, Molecular Cancer Therapeutics.